<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81972">
  <stage>Registered</stage>
  <submitdate>18/12/1995</submitdate>
  <approvaldate>18/12/1995</approvaldate>
  <actrnumber>ACTRN12607000237482</actrnumber>
  <trial_identification>
    <studytitle>A randomised trial investigating the effectiveness of different durations of maximal androgen deprivation prior to and during definitive radiation therapy for locally advanced carcinoma of the prostate</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 96.01 - A randomised trial investigating the effectiveness of different durations of maximal androgen deprivation (using Zoladex and Eulexin) prior to and during definitive radiation therapy for locally advanced carcinoma of the prostate</scientifictitle>
    <utrn />
    <trialacronym>TROG 96.01</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR140</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm A: Maximal androgen deprivation for 2 months prior to and during radiation therapy (total 3 months) Arm B: Maximal androgen deprivation for 5 months prior to and during radiation therapy (total 6 months).
Androgen Deprivation: Zoladex 3.6 mg monthly (every 29 days Sub cutaneous); Eulexin (Flutamide) 250 mg orally three times a day, for either - Two months prior to the commencement of radiation therapy and for one month during radiation therapy (ie 3 months total) or Five months prior to the commencement of radiation therapy and for one month during radiation therapy (ie 6 months total).</interventions>
    <comparator>Arm C: Radiation therapy alone. Radiotherpay Treatment: 66 Gy in 33 daily fractions over 6.5-7 weeks.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cause specific survival</outcome>
      <timepoint>Follow-up schedule is 2 months following radiation therapy, then every 4 months for 18 months. Every 6 months thereafter until 10 years follow up of each patient.  Patients can be seen annually after 5 years if free of all signs of cancer and subject to clinician discretion.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Follow-up schedule is 2 months following radiation therapy, then every 4 months for 18 months. Every 6 months thereafter until 10 years follow up of each patient.  Patients can be seen annually after 5 years if free of all signs of cancer and subject to clinician discretion.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PSA progression</outcome>
      <timepoint>Follow-up schedule is 2 months following radiation therapy, then every 4 months for 18 months. Every 6 months thereafter until 10 years follow up of each patient.  Patients can be seen annually after 5 years if free of all signs of cancer and subject to clinician discretion.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Local progression - diagnosed by DRE, or biopsy or trans-urethral resection performed at least 2 years post radiotherapy (to avoid false positives)</outcome>
      <timepoint>Follow-up schedule is 2 months following radiation therapy, then every 4 months for 18 months. Every 6 months thereafter until 10 years follow up of each patient.  Patients can be seen annually after 5 years if free of all signs of cancer and subject to clinician discretion.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distant progression - diagnosed by bone scan, chest x-ray, CT scan or ultrasound of abdomen</outcome>
      <timepoint>Follow-up schedule is 2 months following radiation therapy, then every 4 months for 18 months. Every 6 months thereafter until 10 years follow up of each patient.  Patients can be seen annually after 5 years if free of all signs of cancer and subject to clinician discretion.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Eligible patients will be those with histologically confirmed, locally advanced adenocarcinoma of the prostate. Included will be patients with primary tumours confined to but diffusely involving more than half of the prostate (clinical stage T2b, c [B2]) or extending beyond the capsule (clinical stage T3, 4 [C]). Patients without regional lymph node involvement demonstrable on CT scan, lymphography or pelvic node sampling- Performance status must be equal to or less than ECOG 1- Eligible patients should be willing to accept the side-effects of maximal androgen deprivation therapy as defined herein- All institutional and ethical guidelines must be followed and all patients must sign an informed consent prior to being placed in the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Stage T1 or T2a (A or B1) disease- Evidence of distant metastases- Lymph node involvement, either clinically, radiologically or pathologically- Radical surgery for carcinoma of the prostate, previous radiation, hormonal manipulation or chemotherapy- Previous or concurrent cancers other than non-melanomatous skin cancer- Major intercurrent physical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment or adequate follow-up either through disablement or limitation of life expectancy to less than 1 year- Performance status of greater than 1 on the ECOG scale</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone /computer</concealment>
    <sequence>Simple randomisation by computer</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>24/06/1996</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>800</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Trans Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress>Newcastle Mater Calvary
Locked Bag 7  HRMC  NSW  2310</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council Project Grant</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Jim Denham</sponsorname>
      <sponsoraddress>University of Newcastle
University Drive
Callaghan  NSW  2308</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is designed primarily to determine whether maximal androgen deprivation, prior to and during radiation therapy, reduces the rate of local failure and appearance of metastases that takes place after radiation therapy. A secondary aim is to determine whether a short period of androgen deprivation (3 months) is as effective as a longer period (6 months). A tertiary aim to see whether the tumour shrinkage caused by androgen deprivation prior to radiation therapy leads to any noticeable reduction in the long-term side-effects of subsequent radiation therapy. By defining the tolerability of and compliance with the regimens used, the final objective is to determine whether androgen deprivation as produced in this study is applicable for widespread use outside of the randomised clinical trial setting.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress>Garran, ACT</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Camperdown, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Hospital</ethicname>
      <ethicaddress>Sydney, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Wentworhville, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Premion - Tugun</ethicname>
      <ethicaddress>Tugun, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Centre QRI</ethicname>
      <ethicaddress>South Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>North Queensland Oncology Service</ethicname>
      <ethicaddress>Townsville. QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Barwon Health - Andrew Love Cancer Care Centre, Geelong Hospital</ethicname>
      <ethicaddress>Geelong, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Hospital</ethicname>
      <ethicaddress>Heidelberg, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>East Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston General Hospital</ethicname>
      <ethicaddress>Launceston, TAS</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress>Nedlands, WA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress>Auckland, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress>Christchurch, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress>Dunedin, Otago, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress>Wellington, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jim Denham</name>
      <address>University of Newcastle
University Drive
Callaghan  NSW  2308</address>
      <phone>+61 2 49211180</phone>
      <fax>+61 2 49211465</fax>
      <email>Jim.Denham@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Allison Steigler</name>
      <address>Department of Radiation Oncology
Locked Bag 7
Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 49211181</phone>
      <fax />
      <email>Allison.Steigler@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Erin Nolan</name>
      <address>Department of Radiation Oncology Locked Bag 7 Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 4014 3912</phone>
      <fax>+61 2 4014 3902</fax>
      <email>Erin.Nolan@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>